Connection
Blair Fennimore to Cost-Benefit Analysis
This is a "connection" page, showing publications Blair Fennimore has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.095 |
|
|
|
-
Scott FI, Hans AK, Gerich ME, Fennimore B, Mamtani R, Vajravelu RK, Lewis JD. Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease. Clin Gastroenterol Hepatol. 2021 10; 19(10):2082-2092.e10.
Score: 0.037
-
Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2020 Jun 19; 14(5):575-587.
Score: 0.036
-
Austin GL, Fennimore B, Ahnen DJ. Can colonoscopy remain cost-effective for colorectal cancer screening? The impact of practice patterns and the Will Rogers phenomenon on costs. Am J Gastroenterol. 2013 Mar; 108(3):296-301.
Score: 0.022